GeneOne Life Science, Inc. (KRX: 011000)
South Korea
· Delayed Price · Currency is KRW 1,995.00
-35.00 (-1.72%)
Dec 20, 2024, 3:30 PM KST
GeneOne Life Science Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Other Revenue | 0 | 0 | - | -0 | - | - | Upgrade
|
| Revenue | 37,969 | 40,203 | 48,718 | 38,700 | 41,503 | 41,241 | Upgrade
|
| Revenue Growth (YoY) | 1.81% | -17.48% | 25.89% | -6.75% | 0.63% | 20.26% | Upgrade
|
| Cost of Revenue | 45,990 | 48,088 | 39,541 | 30,058 | 30,211 | 28,462 | Upgrade
|
| Gross Profit | -8,020 | -7,885 | 9,177 | 8,642 | 11,292 | 12,780 | Upgrade
|
| Selling, General & Admin | 22,403 | 26,627 | 30,867 | 21,498 | 19,651 | 13,730 | Upgrade
|
| Research & Development | 6,115 | 7,043 | 12,147 | 11,441 | 8,396 | 5,874 | Upgrade
|
| Other Operating Expenses | 451.71 | 432.8 | 295.42 | 223.23 | 160.42 | 183.06 | Upgrade
|
| Operating Expenses | 36,430 | 40,483 | 49,376 | 36,170 | 29,821 | 21,046 | Upgrade
|
| Operating Income | -44,450 | -48,368 | -40,199 | -27,527 | -18,529 | -8,266 | Upgrade
|
| Interest Expense | -1,575 | -1,180 | -7,309 | -4,455 | -628.5 | -1,967 | Upgrade
|
| Interest & Investment Income | 204.2 | 518.68 | 6,216 | 1,538 | 561.22 | 259.43 | Upgrade
|
| Currency Exchange Gain (Loss) | -309.95 | 107.21 | 278.95 | 4,361 | -2,424 | 91.22 | Upgrade
|
| Other Non Operating Income (Expenses) | 5,876 | 3,569 | 2,958 | 9,638 | 2,791 | 2,738 | Upgrade
|
| EBT Excluding Unusual Items | -40,255 | -45,353 | -38,056 | -16,445 | -18,230 | -7,145 | Upgrade
|
| Gain (Loss) on Sale of Investments | 5.55 | 4.25 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 1.73 | 3.4 | 1.31 | -106.93 | 3.24 | - | Upgrade
|
| Asset Writedown | -32,309 | -32,309 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | 1,018 | - | - | Upgrade
|
| Pretax Income | -72,557 | -77,655 | -38,054 | -15,534 | -18,226 | -7,145 | Upgrade
|
| Income Tax Expense | 133.35 | 113.45 | 95.79 | 353.75 | 421.99 | 474.03 | Upgrade
|
| Net Income | -72,691 | -77,768 | -38,150 | -15,888 | -18,648 | -7,619 | Upgrade
|
| Net Income to Common | -72,691 | -77,768 | -38,150 | -15,888 | -18,648 | -7,619 | Upgrade
|
| Shares Outstanding (Basic) | 79 | 78 | 77 | 74 | 60 | 32 | Upgrade
|
| Shares Outstanding (Diluted) | 79 | 78 | 77 | 74 | 60 | 32 | Upgrade
|
| Shares Change (YoY) | 1.93% | 0.34% | 4.37% | 22.98% | 88.03% | 1.93% | Upgrade
|
| EPS (Basic) | -919.40 | -1000.23 | -492.35 | -214.00 | -308.90 | -237.28 | Upgrade
|
| EPS (Diluted) | -919.97 | -1000.23 | -492.35 | -214.00 | -309.00 | -237.33 | Upgrade
|
| Free Cash Flow | -24,121 | -27,345 | -69,419 | -87,291 | -32,069 | -4,107 | Upgrade
|
| Free Cash Flow Per Share | -305.08 | -351.70 | -895.90 | -1175.77 | -531.20 | -127.91 | Upgrade
|
| Gross Margin | -21.12% | -19.61% | 18.84% | 22.33% | 27.21% | 30.99% | Upgrade
|
| Operating Margin | -117.07% | -120.31% | -82.51% | -71.13% | -44.65% | -20.04% | Upgrade
|
| Profit Margin | -191.44% | -193.44% | -78.31% | -41.05% | -44.93% | -18.47% | Upgrade
|
| Free Cash Flow Margin | -63.53% | -68.02% | -142.49% | -225.56% | -77.27% | -9.96% | Upgrade
|
| EBITDA | -26,918 | -35,592 | -34,776 | -22,877 | -14,508 | -4,846 | Upgrade
|
| EBITDA Margin | -70.89% | -88.53% | -71.38% | -59.11% | -34.96% | -11.75% | Upgrade
|
| D&A For EBITDA | 17,532 | 12,776 | 5,424 | 4,650 | 4,021 | 3,420 | Upgrade
|
| EBIT | -44,450 | -48,368 | -40,199 | -27,527 | -18,529 | -8,266 | Upgrade
|
| EBIT Margin | -117.07% | -120.31% | -82.51% | -71.13% | -44.65% | -20.04% | Upgrade
|
| Advertising Expenses | - | 196.96 | 341.71 | 194.45 | 168.08 | 209.12 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.